Compare Aptiv PLC (APTV) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aptiv PLC vs TG Therapeutics Inc — how do they compare? Aptiv PLC trades at $48.5 (market cap $10.30B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Aptiv PLC is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Aptiv PLC nearer its low. Which is the better fit depends on your goals.
| APTV | TGTX | |
|---|---|---|
Market Cap | $10.30B | $7.64B |
Sector | Consumer Cyclical | Health |
52-Week High | $76.82 | $59.06 |
52-Week Low | $46.30 | $26.94 |
Enterprise Value | $15.23B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
APTV trades at $48.38, down 2.87% on the day, reflecting bearish technical signals and recent guidance cuts. The stock shows strong valuation metrics with a P/E of 22.45 and P/S of 0.52, but profitability is weak with a net margin of 1.07%. Recent Q2 2026 earnings beat estimates, but the company lowered its full-year outlook due to China demand issues and launch delays, pressuring investor sentiment.
The outlook is mixed: low valuation and analyst consensus of $70.09 target suggest upside, but near-term execution risks and cash flow pressures create uncertainty. Investment opportunity hinges on margin recovery and China market stabilization, while risks include sustained guidance cuts and competitive pressures in automotive technology.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Aptiv PLC
Aptiv's signal and power solutions segment supplies components and systems that make up a vehicle's electrical system backbone, including wiring assemblies and harnesses, connectors, electrical centers, and hybrid electrical systems. The advanced safety and user experience segment provides body controls, infotainment and connectivity systems, passive and active safety electronics, advanced driver-assist technologies, and displays, as well as the development of software for these systems. Aptiv's largest customer is General Motors at roughly 12% of 2021 revenue, including sales to GM's Shanghai joint venture, followed by Stellantis at 11%, and Volkswagen at 9%. North America and Europe represented approximately 38% and 33% of total 2019 revenue, respectively.
Read more on APTV →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
